ImmunoGen CEO: Solving Cancer’s Access Challenge With Data, Differentiation And A Big Dose of Bipartisanship
Executive Summary
ImmunoGen CEO Mark Enyedy, a leading proponent of targeted ADC oncologics, explains to In Vivo how high risk – and dogged resilience – are central features of a challenging innovative landscape in cancer today. Despite some recent setbacks on the road to commercialization, science will continue to transform, bolstered by the industry's financial commitments; revolutionary new data sources, validated by patient-centered outcomes; and that persistent human intangible called hope.